Document And Entity Information
Document And Entity Information | 3 Months Ended |
Jul. 31, 2021shares | |
Document Information [Line Items] | |
Entity Central Index Key | 0000715812 |
Entity Registrant Name | BIOSYNERGY INC |
Amendment Flag | false |
Current Fiscal Year End Date | --04-30 |
Document Fiscal Period Focus | Q1 |
Document Fiscal Year Focus | 2022 |
Document Type | 10-Q |
Document Quarterly Report | true |
Document Period End Date | Jul. 31, 2021 |
Document Transition Report | false |
Entity File Number | 0-12459 |
Entity Incorporation, State or Country Code | IL |
Entity Tax Identification Number | 36-2880990 |
Entity Address, Address Line One | 1940 East Devon Avenue |
Entity Address, City or Town | Elk Grove Village |
Entity Address, State or Province | IL |
Entity Address, Postal Zip Code | 60007 |
City Area Code | 847 |
Local Phone Number | 956-0471 |
Entity Current Reporting Status | Yes |
Entity Interactive Data Current | Yes |
Entity Filer Category | Non-accelerated Filer |
Entity Small Business | true |
Entity Emerging Growth Company | false |
Entity Shell Company | false |
Entity Common Stock, Shares Outstanding | 14,935,511 |
Balance Sheets (Current Period
Balance Sheets (Current Period Unaudited) - USD ($) | Jul. 31, 2021 | Apr. 30, 2021 |
Current Assets | ||
Cash | $ 1,297,167 | $ 1,250,581 |
Accounts receivable. Trade (net of allowance for doubtful accounts of $500 at July 31, 2021 and April 30, 2021 | 130,515 | 264,509 |
Inventories | 128,609 | 145,178 |
Prepaid expenses | 29,620 | 34,261 |
Total Current Assets | 1,585,911 | 1,694,529 |
Property, Plant and Equipment | ||
Equipment | 176,812 | 176,812 |
Leasehold improvements | 25,809 | 25,809 |
Property, Plant and Equipment, Gross, Ending Balance | 202,621 | 202,621 |
Less accumulated depreciation and amortization | (200,674) | (199,558) |
Total Equipment and Leasehold Improvements Net | 1,947 | 3,063 |
Operating Lease Right of Use | ||
Operating Lease Right of Use Asset | 72,428 | 96,570 |
Total Operating Lease Right of Use Asset | 72,428 | 96,570 |
Other Assets | ||
Patents less accumulated amortization | 88,004 | 91,415 |
Deposits | 5,937 | 5,937 |
Deferred Tax Asset | 10,329 | 0 |
Total other assets | 104,270 | 97,352 |
Assets, Total | 1,764,556 | 1,891,514 |
Current Liabilities | ||
Accounts payable | 26,497 | 3,189 |
Accrued compensation and payroll taxes | 9,775 | 11,689 |
Accrued vacation | 1,228 | 14,125 |
Other accrued liabilities | 3,186 | 543 |
Operating lease liability | 73,485 | 97,980 |
Total Current Liabilities | 114,171 | 127,526 |
Long term liabilities | ||
Deferred income taxes | 24,992 | |
Total Long Term Liabilities | 24,992 | |
Stockholders’ Equity | ||
Common stock, no par value: 20,000,000 authorized shares Issued: 14,935,511 as of July 31, 2021 and April 30, 2021 | 660,988 | 660,988 |
Receivable from affiliate | (24,862) | (24,862) |
Retained earnings | 1,014,259 | 1,102,870 |
Total Stockholders’ Equity | 1,650,385 | 1,738,996 |
Liabilities and Equity, Total | $ 1,764,556 | $ 1,891,514 |
Balance Sheets (Current Perio_2
Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ / shares in Thousands | Jul. 31, 2021 | Apr. 30, 2021 |
Net of allowance for doubtful accounts | $ 500 | $ 500 |
Common stock, par value (in dollars per share) | $ 0 | $ 0 |
Common stock, shares authorized (in shares) | 20,000,000 | 20,000,000 |
Common stock, shares issued (in shares) | 14,935,511 | 14,935,511 |
Statements of Operations (Unaud
Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
Jul. 31, 2021 | Jul. 31, 2020 | |
Net sales | $ 174,838 | $ 291,451 |
Cost of sales | 104,913 | 111,883 |
Gross profit | 69,925 | 179,568 |
Operating expenses | ||
Marketing | 34,110 | 45,086 |
General and administrative | 131,794 | 113,540 |
Research and development | 29,266 | 40,053 |
Total Operating Expenses | 195,170 | 198,679 |
Loss from operations | (125,245) | (19,111) |
Other income | ||
Interest income | 58 | 142 |
Other income | 1,255 | 480 |
Total Other Income | 1,313 | 622 |
Net Loss before income taxes | (123,932) | (18,489) |
Benefit for income taxes | (35,321) | (5,269) |
Net Loss | $ (88,611) | $ (13,220) |
Net Loss per common share - basic and diluted (in dollars per share) | $ (59) | $ (8) |
Weighted-Average Shares of Common Stock Outstanding - Basic and Diluted (in shares) | 14,935,511 | 14,935,511 |
Statement of Shareholders' Equi
Statement of Shareholders' Equity (Unaudited) - 3 months ended Jul. 31, 2021 - USD ($) | Common Stock [Member] | Receivable from Affiliate [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Apr. 30, 2021 | 14,935,511 | |||
Balance at Apr. 30, 2021 | $ 660,988 | $ (24,862) | $ 1,102,870 | $ 1,738,996 |
Net Loss | $ 0 | 0 | (88,611) | (88,611) |
Balance (in shares) at Jul. 31, 2021 | 14,935,511 | |||
Balance at Jul. 31, 2021 | $ 660,988 | $ (24,862) | $ 1,014,259 | $ 1,650,385 |
Statements of Cash Flows (Unaud
Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
Jul. 31, 2021 | Jul. 31, 2020 | |
Cash flows from operating activities | ||
Net loss | $ (88,611) | $ (13,220) |
Adjustments to reconcile net loss to cash provided by operating activities | ||
Deferred Taxes | (35,321) | 0 |
Depreciation and amortization | 4,526 | 4,526 |
Noncash lease expense | 24,143 | 24,143 |
Changes in assets and liabilities | ||
Accounts receivable | 133,994 | 36,414 |
Inventories | 16,569 | 77 |
Prepaid expenses | 4,641 | (1,368) |
Accounts payable and accrued expenses | 11,140 | (17,328) |
Building lease liability for right of use asset | (24,495) | (23,790) |
Total adjustments | 135,197 | 22,674 |
Net cash provided by operating activities | 46,586 | 9,454 |
Increase in cash and cash equivalents | 46,586 | 9,454 |
Cash and cash equivalents beginning period | 1,250,581 | 1,245,282 |
Cash and cash equivalents ending period | 1,297,167 | 1,254,736 |
Supplemental cash flow information | ||
Interest paid | 0 | 0 |
Income taxes paid | $ 0 | $ 0 |
Note 1 - Company Organization a
Note 1 - Company Organization and Description | 3 Months Ended |
Jul. 31, 2021 | |
Notes to Financial Statements | |
Business Description and Basis of Presentation [Text Block] | Note 1 In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments, consisting of normal recurring adjustments which are necessary for a fair presentation of the financial position and results of operations for the periods presented. The unaudited condensed financial statements have been prepared in accordance with the instructions to Form 10 not April 30, 2021 10 three July 31, 2021 not Biosynergy, Inc. (the Company) was incorporated under the laws of the State of Illinois on February 9, 1976. July 31, 2021 July 31, 2020. |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 3 Months Ended |
Jul. 31, 2021 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | Note 2 Cash The Company maintains all of its cash in various bank deposit accounts, which at times may No Receivables Receivables are carried at original invoice less estimates made for doubtful receivables. Management determines the allowances for doubtful accounts by reviewing and identifying troubled accounts on a periodic basis and by using historical experience applied to an aging of accounts. A receivable is considered to be past due if any portion of the receivable balance is outstanding beyond the stipulated due date. Receivables are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded when received. Inventories Inventories are valued at the lower of cost or market using the FIFO ( first first Depreciation Equipment and leasehold improvements are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Repairs and maintenance are charged to expense as incurred; renewals and betterments which significantly extend the useful lives of existing equipment are capitalized. Significant leasehold improvements are capitalized and amortized over the term of the lease; equipment is depreciated over three ten Depreciation expense was $1,116 for each of the three July 31, 2021 2020, Prepaid Expenses Certain expenses, primarily insurance and income taxes, have been prepaid and will be used within one Revenue Recognition The Company accounts for revenue in accordance with ASU 2014 09, 606 2014 09 five The components as it relates to the Company are as follows: • The Company’s revenue is primarily generated from the sales of products directly to customers or through distribution channels, based on purchase orders and not • ASU No. 2014 09 no Shipping and Handling Shipping and handling fees billed to customer, if any, are netted against the related costs which are included in cost of sales. The net cost is not Income Taxes Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes related primarily to differences in the methods of accounting for patents, inventories, certain accrued expenses and bad debt expenses for financial and income tax reporting purposes. The deferred income taxes represent the future tax consequences of those differences, which will be taxable in the future. The Company files tax returns in the U.S. federal jurisdiction and with the state of Illinois. Various tax years remain open to examinations, generally for three no The benefit for income taxes consists of the following components for the three July 31: 2021 2020 Current Federal $ - $ (3,513 ) State - (1,756 ) Deferred (35,321 ) - Provision for Income Taxes $ (35,321 ) $ (5,269 ) The differences between the U.S. federal statutory tax rate and the Company’s effective tax rate are as follows: Period ended July 31, 2021 2020 U.S. federal statutory tax rate (21.0 %) (21.0 %) State income tax expense, net of Federal tax benefit (7.5 ) (7 .5 ) Effective Tax Rate (28.5 %) (28.5 %) Research and Development and Patents Research and development expenditures are charged to operations as incurred. The costs of obtaining patents, primarily legal fees, are capitalized and, once obtained, are amortized over the life of the respective patent on the straight-line method. Patent amortization expense for each of the three July 31, 2021 2020 Patents relate to products that have been developed and are being marketed by the Company. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Income Per Common Share Income per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Basic and diluted net income per common share is the same for the 1 st July 31, 2021 2020 no Comprehensive Income Components of comprehensive income include amounts that are included in the comprehensive income but are excluded from net income. During the three July 31, 2021 2020, no Fair Value of Financial Instruments The Company evaluates its financial instruments based on current market interest rates relative to stated interest rates, length to maturity and the existence of readily determinable market prices. Based on the Company’s analysis, the fair value of financial instruments recorded on the balances sheets as of July 31, 2021 April 30, 2021, Segments Accounting standards have established annual reporting standards for an enterprise’s operating segments and related disclosures about its products, services, geographic areas and major customers. The Company’s operations were a single reportable segment and an international segment. The international segment operations are immaterial. See Note 7. Recent Accounting Pronouncements The FASB issues ASUs to amend the authoritative literature in Accounting Standards Certification (ASC). There have been a number of ASUs to date that amend the original text of ASCs. Those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not not |
Note 3 - Inventories
Note 3 - Inventories | 3 Months Ended |
Jul. 31, 2021 | |
Notes to Financial Statements | |
Inventory Disclosure [Text Block] | Note 3 Inventories Components of inventories are as follows: July 31, 2021 April 30, 2021 Raw materials $ 116,854 $ 108,604 Work-in-process 5,715 25,371 Finished goods 6,040 11,203 $ 128,609 $ 145,178 |
Note 4 - Common Stock
Note 4 - Common Stock | 3 Months Ended |
Jul. 31, 2021 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | Note 4 Common Stock The Company’s common stock is traded in the over-the-counter market. However, there is no not |
Note 5 - Related Party Transact
Note 5 - Related Party Transactions | 3 Months Ended |
Jul. 31, 2021 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | Note 5 The Company and its affiliates are related through common stock ownership as follows as of July 31, 2021: Stock of Affiliates Biosynergy, Inc. F.K. Suzuki International, Inc. Medlab, Inc. F.K. Suzuki International, Inc 30.0% -% 100.0% Fred K. Suzuki, Officer 4.1 30.0 - Jeanne S. Addis, Trustee - 28.1 - Mary K. Friske 0.3 0.7 - Laurence C. Mead 0.4 10.0 - Beverly R. Suzuki 2.7 - - Lauane C. Addis, Director - - - Malcolm MacCoun, Director - - - As of July 31, 2021 April 30, 2021, No A board member provided a variety of legal services to the Company in his capacity as a partner in a law firm. Fees for such legal services were approximately $29,549 and $4,832 for the three July 31, 2021 2020, |
Note 6 - Lease Commitments
Note 6 - Lease Commitments | 3 Months Ended |
Jul. 31, 2021 | |
Notes to Financial Statements | |
Leases of Lessee Disclosure [Text Block] | Note 6 Lease Commitments On February 25, 2016, 842, 12 February 2020, two May 1, 2020 April 30, 2022. two not two The operating lease expense for the three July 31, 2021 2020 Maturities of lease liabilities as of July 31, 2021 Year Ending April 30: 2022 $ 73,485 |
Note 7 - Customer Concentration
Note 7 - Customer Concentrations | 3 Months Ended |
Jul. 31, 2021 | |
Notes to Financial Statements | |
Concentration Risk Disclosure [Text Block] | Note 7 Customer Concentrations Shipments to one customer amounted to 33.17% of sales during the first three 2022 2021 July 31, 2021, July 31, 2020. first three 2022 first three 2021. July 31, 2021, July 31, 2020. The Company had export sales of $3,750 during the first three 2022, first three 2021. not not |
Note 8 - COVID-19 Pandemic and
Note 8 - COVID-19 Pandemic and Other Risks | 3 Months Ended |
Jul. 31, 2021 | |
Notes to Financial Statements | |
Covid19 Pandemic [Text Block] | Note 8 COVID- 19 The Company will face challenges in 2021 2022 19 April 30, 2021. July 31, 2021, third not April 30, 2021 July 31, 2021. third |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 3 Months Ended |
Jul. 31, 2021 | |
Accounting Policies [Abstract] | |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash The Company maintains all of its cash in various bank deposit accounts, which at times may No |
Receivable [Policy Text Block] | Receivables Receivables are carried at original invoice less estimates made for doubtful receivables. Management determines the allowances for doubtful accounts by reviewing and identifying troubled accounts on a periodic basis and by using historical experience applied to an aging of accounts. A receivable is considered to be past due if any portion of the receivable balance is outstanding beyond the stipulated due date. Receivables are written off when deemed uncollectible. Recoveries of receivables previously written off are recorded when received. |
Inventory, Policy [Policy Text Block] | Inventories Inventories are valued at the lower of cost or market using the FIFO ( first first |
Property, Plant and Equipment, Policy [Policy Text Block] | Depreciation Equipment and leasehold improvements are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Repairs and maintenance are charged to expense as incurred; renewals and betterments which significantly extend the useful lives of existing equipment are capitalized. Significant leasehold improvements are capitalized and amortized over the term of the lease; equipment is depreciated over three ten Depreciation expense was $1,116 for each of the three July 31, 2021 2020, |
Prepaid Expenses [Policy Text Block] | Prepaid Expenses Certain expenses, primarily insurance and income taxes, have been prepaid and will be used within one |
Revenue [Policy Text Block] | Revenue Recognition The Company accounts for revenue in accordance with ASU 2014 09, 606 2014 09 five The components as it relates to the Company are as follows: • The Company’s revenue is primarily generated from the sales of products directly to customers or through distribution channels, based on purchase orders and not • ASU No. 2014 09 no |
Shipping and Handling Cost, Policy [Policy Text Block] | Shipping and Handling Shipping and handling fees billed to customer, if any, are netted against the related costs which are included in cost of sales. The net cost is not |
Income Tax, Policy [Policy Text Block] | Income Taxes Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes related primarily to differences in the methods of accounting for patents, inventories, certain accrued expenses and bad debt expenses for financial and income tax reporting purposes. The deferred income taxes represent the future tax consequences of those differences, which will be taxable in the future. The Company files tax returns in the U.S. federal jurisdiction and with the state of Illinois. Various tax years remain open to examinations, generally for three no The benefit for income taxes consists of the following components for the three July 31: 2021 2020 Current Federal $ - $ (3,513 ) State - (1,756 ) Deferred (35,321 ) - Provision for Income Taxes $ (35,321 ) $ (5,269 ) The differences between the U.S. federal statutory tax rate and the Company’s effective tax rate are as follows: Period ended July 31, 2021 2020 U.S. federal statutory tax rate (21.0 %) (21.0 %) State income tax expense, net of Federal tax benefit (7.5 ) (7 .5 ) Effective Tax Rate (28.5 %) (28.5 %) |
Research and Development Expense, Policy [Policy Text Block] | Research and Development and Patents Research and development expenditures are charged to operations as incurred. The costs of obtaining patents, primarily legal fees, are capitalized and, once obtained, are amortized over the life of the respective patent on the straight-line method. Patent amortization expense for each of the three July 31, 2021 2020 Patents relate to products that have been developed and are being marketed by the Company. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
Earnings Per Share, Policy [Policy Text Block] | Income Per Common Share Income per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the period. Basic and diluted net income per common share is the same for the 1 st July 31, 2021 2020 no |
Comprehensive Income, Policy [Policy Text Block] | Comprehensive Income Components of comprehensive income include amounts that are included in the comprehensive income but are excluded from net income. During the three July 31, 2021 2020, no |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Instruments The Company evaluates its financial instruments based on current market interest rates relative to stated interest rates, length to maturity and the existence of readily determinable market prices. Based on the Company’s analysis, the fair value of financial instruments recorded on the balances sheets as of July 31, 2021 April 30, 2021, |
Segment Reporting, Policy [Policy Text Block] | Segments Accounting standards have established annual reporting standards for an enterprise’s operating segments and related disclosures about its products, services, geographic areas and major customers. The Company’s operations were a single reportable segment and an international segment. The international segment operations are immaterial. See Note 7. |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements The FASB issues ASUs to amend the authoritative literature in Accounting Standards Certification (ASC). There have been a number of ASUs to date that amend the original text of ASCs. Those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not not |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Jul. 31, 2021 | |
Notes Tables | |
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | 2021 2020 Current Federal $ - $ (3,513 ) State - (1,756 ) Deferred (35,321 ) - Provision for Income Taxes $ (35,321 ) $ (5,269 ) |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | Period ended July 31, 2021 2020 U.S. federal statutory tax rate (21.0 %) (21.0 %) State income tax expense, net of Federal tax benefit (7.5 ) (7 .5 ) Effective Tax Rate (28.5 %) (28.5 %) |
Note 3 - Inventories (Tables)
Note 3 - Inventories (Tables) | 3 Months Ended |
Jul. 31, 2021 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | July 31, 2021 April 30, 2021 Raw materials $ 116,854 $ 108,604 Work-in-process 5,715 25,371 Finished goods 6,040 11,203 $ 128,609 $ 145,178 |
Note 5 - Related Party Transa_2
Note 5 - Related Party Transactions (Tables) | 3 Months Ended |
Jul. 31, 2021 | |
Notes Tables | |
Schedule of Stock Affiliates [Table Text Block] | Stock of Affiliates Biosynergy, Inc. F.K. Suzuki International, Inc. Medlab, Inc. F.K. Suzuki International, Inc 30.0% -% 100.0% Fred K. Suzuki, Officer 4.1 30.0 - Jeanne S. Addis, Trustee - 28.1 - Mary K. Friske 0.3 0.7 - Laurence C. Mead 0.4 10.0 - Beverly R. Suzuki 2.7 - - Lauane C. Addis, Director - - - Malcolm MacCoun, Director - - - |
Note 6 - Lease Commitments (Tab
Note 6 - Lease Commitments (Tables) | 3 Months Ended |
Jul. 31, 2021 | |
Notes Tables | |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | Year Ending April 30: 2022 $ 73,485 |
Note 1 - Company Organization_2
Note 1 - Company Organization and Description (Details Textual) | 3 Months Ended | |
Jul. 31, 2021 | Jul. 31, 2020 | |
Product Concentration Risk [Member] | Revenue Benchmark [Member] | HemoTemp II Blood Monitoring Device [Member] | ||
Concentration Risk, Percentage | 87.52% | 86.40% |
Note 2 - Summary of Significa_3
Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) | 3 Months Ended | |
Jul. 31, 2021 | Jul. 31, 2020 | |
Depreciation, Total | $ 1,116 | $ 1,116 |
Amortization of Intangible Assets, Total | $ 3,411 | $ 3,411 |
Equipment [Member] | Minimum [Member] | ||
Property, Plant and Equipment, Useful Life (Year) | 3 years | |
Equipment [Member] | Maximum [Member] | ||
Property, Plant and Equipment, Useful Life (Year) | 10 years |
Note 2 - Summary of Significa_4
Note 2 - Summary of Significant Accounting Policies - Components of Income Tax Expense Benefit (Details) - USD ($) | 3 Months Ended | |
Jul. 31, 2021 | Jul. 31, 2020 | |
Federal | $ 0 | $ (3,513) |
State | 0 | (1,756) |
Deferred | (35,321) | 0 |
Provision for Income Taxes | $ (35,321) | $ (5,269) |
Note 2 - Summary of Significa_5
Note 2 - Summary of Significant Accounting Policies - Effective Income Tax Rate Reconciliation (Details) | 3 Months Ended | |
Jul. 31, 2021 | Jul. 31, 2020 | |
U.S. federal statutory tax rate | (21.00%) | (21.00%) |
State income tax expense, net of Federal tax benefit | (7.50%) | (7.50%) |
Effective Tax Rate | (28.50%) | (28.50%) |
Note 3 - Inventories - Schedule
Note 3 - Inventories - Schedule of Inventory (Details) - USD ($) | Jul. 31, 2021 | Apr. 30, 2021 |
Raw materials | $ 116,854 | $ 108,604 |
Work-in-process | 5,715 | 25,371 |
Finished goods | 6,040 | 11,203 |
Inventory, Gross, Total | $ 128,609 | $ 145,178 |
Note 5 - Related Party Transa_3
Note 5 - Related Party Transactions (Details Textual) - USD ($) | 3 Months Ended | ||
Jul. 31, 2021 | Jul. 31, 2020 | Apr. 30, 2021 | |
Due from Affiliate, Noncurrent | $ 24,862 | $ 24,862 | |
F. K. Suzuki International, Inc. [Member] | |||
Due from Affiliate, Noncurrent | 24,862 | $ 24,862 | |
F. K. Suzuki International, Inc. [Member] | Corporate Compliance Costs [Member] | |||
Related Party Transaction, Amounts of Transaction | $ 29,549 | $ 4,832 |
Note 5 - Related Party Transa_4
Note 5 - Related Party Transactions - Schedule of Stock Affiliates (Details) | Jul. 31, 2021 |
Biosynergy, Inc. [Member] | F. K. Suzuki International, Inc. [Member] | |
Ownership percentage | 30.00% |
Biosynergy, Inc. [Member] | Fred K. Suzuki, Officer [Member] | |
Ownership percentage | 4.10% |
Biosynergy, Inc. [Member] | Jeanne S. Addis, Trustee [Member] | |
Ownership percentage | 0.00% |
Biosynergy, Inc. [Member] | Mary K. Friske, Officer [Member] | |
Ownership percentage | 0.30% |
Biosynergy, Inc. [Member] | Laurence C. Mead, Officer [Member] | |
Ownership percentage | 0.40% |
Biosynergy, Inc. [Member] | Beverly R. Suzuki [Member] | |
Ownership percentage | 2.70% |
Biosynergy, Inc. [Member] | Lauane C. Addis, Officer [Member] | |
Ownership percentage | 0.00% |
Biosynergy, Inc. [Member] | Malcom MacCoun, Director [Member] | |
Ownership percentage | 0.00% |
F. K. Suzuki International, Inc. [Member] | F. K. Suzuki International, Inc. [Member] | |
Ownership percentage | 0.00% |
F. K. Suzuki International, Inc. [Member] | Fred K. Suzuki, Officer [Member] | |
Ownership percentage | 30.00% |
F. K. Suzuki International, Inc. [Member] | Jeanne S. Addis, Trustee [Member] | |
Ownership percentage | 28.10% |
F. K. Suzuki International, Inc. [Member] | Mary K. Friske, Officer [Member] | |
Ownership percentage | 0.70% |
F. K. Suzuki International, Inc. [Member] | Laurence C. Mead, Officer [Member] | |
Ownership percentage | 10.00% |
F. K. Suzuki International, Inc. [Member] | Beverly R. Suzuki [Member] | |
Ownership percentage | 0.00% |
F. K. Suzuki International, Inc. [Member] | Lauane C. Addis, Officer [Member] | |
Ownership percentage | 0.00% |
F. K. Suzuki International, Inc. [Member] | Malcom MacCoun, Director [Member] | |
Ownership percentage | 0.00% |
Medlab, Inc. [Member] | F. K. Suzuki International, Inc. [Member] | |
Ownership percentage | 100.00% |
Medlab, Inc. [Member] | Fred K. Suzuki, Officer [Member] | |
Ownership percentage | 0.00% |
Medlab, Inc. [Member] | Jeanne S. Addis, Trustee [Member] | |
Ownership percentage | 0.00% |
Medlab, Inc. [Member] | Mary K. Friske, Officer [Member] | |
Ownership percentage | 0.00% |
Medlab, Inc. [Member] | Laurence C. Mead, Officer [Member] | |
Ownership percentage | 0.00% |
Medlab, Inc. [Member] | Beverly R. Suzuki [Member] | |
Ownership percentage | 0.00% |
Medlab, Inc. [Member] | Lauane C. Addis, Officer [Member] | |
Ownership percentage | 0.00% |
Medlab, Inc. [Member] | Malcom MacCoun, Director [Member] | |
Ownership percentage | 0.00% |
Note 6 - Lease Commitments (Det
Note 6 - Lease Commitments (Details Textual) - USD ($) | 3 Months Ended | ||
Jul. 31, 2021 | Jul. 31, 2020 | Feb. 28, 2020 | |
Lessee, Operating Lease, Term of Contract (Year) | 2 years | ||
Operating Lease, Expense | $ 24,143 | $ 24,143 |
Note 6 - Lease Commitments - Op
Note 6 - Lease Commitments - Operating Lease Liability Maturity (Details) | Jul. 31, 2021USD ($) |
2022 | $ 73,485 |
Note 7 - Customer Concentrati_2
Note 7 - Customer Concentrations (Details Textual) | 3 Months Ended | |
Jul. 31, 2021USD ($) | Jul. 31, 2020USD ($) | |
Export Sales | $ 3,750 | $ 11,640 |
Customer One[Member] | ||
Accounts Receivable, before Allowance for Credit Loss | 61,999 | 82,460 |
Customer Two [Member] | ||
Accounts Receivable, before Allowance for Credit Loss | $ 59,176 | $ 107,544 |
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | ||
Number of Customers | 1 | 1 |
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer One[Member] | ||
Concentration Risk, Percentage | 33.17% | 33.29% |
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer Two [Member] | ||
Concentration Risk, Percentage | 39.98% | 34.66% |
Note 8 - COVID-19 Pandemic an_2
Note 8 - COVID-19 Pandemic and Other Risks (Details Textual) | 3 Months Ended |
Jul. 31, 2021 | |
Number of Employees Resigned | 3 |